Compare ADMA Biologics Inc (ADMA) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Wells Fargo & Co — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Wells Fargo & Co trades at $87.68 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 121.4× ADMA Biologics Inc's market cap, and Wells Fargo & Co pays a 2.29% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WFC | |
|---|---|---|
Market Cap | $2.18B | $264.66B |
Sector | Health | Financials |
52-Week High | $20.38 | $96.40 |
52-Week Low | $7.60 | $73.42 |
Enterprise Value | $2.25B | — |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Wells Fargo (WFC) trades at $87.25, down 0.4% today, with a bullish technical outlook from moving averages and a consensus price target of $97.64. The stock shows strong profitability with a net income margin of 25.97% and ROE of 13.13%, supported by steady revenue growth to $83.70 billion in 2025. Recent news highlights the launch of tokenized deposits for corporate clients, reflecting innovation in digital banking services.
The stock presents a value opportunity with a P/E of 12.68, but risks include volatile cash flows and recent earnings misses. Upside is driven by analyst optimism and dividend increases, while headwinds involve economic sensitivity and competitive pressures in banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
